About Us
Our Technology
Our Pipeline
Patients
Our News
More
May 6, 2025
Akamis Bio Broadens Leadership Team with Key Executive Appointments
Apr 3, 2025
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
Dec 17, 2024
Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
Oct 23, 2024
Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
October 3, 2023
Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer
July 6, 2023
Akamis Bio Strengthens Leadership Team with Key Executive Appointments
February 16, 2023
Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research InstituteAnnounce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer
January 5, 2023
Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics
August 11, 2022
PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer